Research introduction

I. Research background and research purposes
Research background
Pancreaticoduodenectomy (PD) is one of the most complicated surgical procedures in abdominal surgery. It includes not only the removal of the head of the pancreas, the common bile duct, the distal stomach, the duodenum, the proximal jejunum, the gallbladder and other organs. It also involves the tedious reconstruction of the digestive tract. It is considered to be the standard surgical method for the treatment of pancreatic head tumors, lower common bile duct tumors, duodenal tumors and other diseases.
Due to the change of surgical instruments and the improvement of surgical techniques, Minimally invasive surgery (MIS) is increasingly used in pancreatic surgery. First reported by Gagner et al., the first laparoscopic pancreaticoduodenectomy was performed in 1994. Then more and more laparoscopic pancreatic surgery is gradually carried out. Many scholars believe that compared with traditional open surgery, laparoscopic surgery has the advantages of less impact on patients, shorter hospital stay, less intraoperative blood loss, etc. Can achieve oncological prognosis and long-term survival similar to open surgery. However, laparoscopic surgery also has problems such as long operation time and high cost. To date, many studies have shown that 3D laparoscopic techniques have significant advantages in gastric, renal, and cervical surgery. However, there are few reports on its application in pancreatic surgery. Only a few meta-analyses were compared Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01) a multicenter randomized controlled trial Informed Consent Version date2018-03-20 Ver 1.0
between laparoscopic and open surgery, but the quality of the included literature was not high.
However, the current research has some shortcomings. Different types of surgical methods were collectively referred to as minimally invasive surgery. The baselines of patients were different between different studies. Most of the studies included a small number of patients, high data heterogeneity, and different levels of surgery. The method did not give specific reports and the study could not provide detailed oncology results and long-term follow-up data.
Research purposes
The purpose of this study was to evaluate the safety and efficacy of total laparoscopic pancreaticoduodenectomy compared with open pancreaticoduodenectomy.
Study participants and expected number of participants
This study included 14 medical center all over China. The number of participants in this study is expected to be 656.
II. Who can participate in this study?
1. The patient is ≥18 years old and younger than 75 years old; 2. Highly suspected or histological evidence of pancreas, bile duct, duodenal malignancy, etc.; 3. Those who are highly suspected of malignant tumors but unable to obtain pathological evidence; 4. Benign lesions originate from the pancreas, bile duct, duodenum, stomach and other pancreaticoduodenectomy; 5. The assessment team assessed no significant vascular invasion based on abdominal imaging data before surgery; 6. The subject understands and can cooperate with the study; 7. Subjects can provide and sign written informed consent prior to conducting research-related operations; 8. According to the NCCN guidelines, patients will benefit from this therapeutic procedure.
Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01) a multicenter randomized controlled trial
Informed Consent Version date2018-03-20 Ver 1.0 implantation, distant lymph node metastasis, liver or other organ metastasis; 2. Subjects need to undergo pancreatic body resection, middle pancreatic resection or total pancreatectomy and other surgical methods; 3. According to the American Society of Anesthesiologists (ASA) the score greater than 4 points, there is a high degree of surgical risk; 4. The vascular invasion was assessed by the assessment team based on abdominal imaging data before surgery, and patients requiring combined vascular resection during surgery; 5. Patients with other tumors at the same time; 6. Radical surgery cannot benefit, only palliative surgery will done;
IV. What will be done if you participate in the research?
If you meet the inclusion criteria and agree to participate, you will be tested according to the following steps: divided into two groups according to the study plan, respectively, undergoing laparoscopic and open surgery, both groups undergo pancreaticoduodenectomy, you may be assigned In any group, whether you are enrolling or operating in surgery, your interests will be the first consideration. All patients underwent routine nursing of biliary and pancreatic surgery, and collected various indexes before, during and after surgery, including but not limited to blood routine, blood biochemistry, tumor markers, blood loss, anastomosis, and complications. Conduct safety and efficacy assessments and judgments. At the same time, follow-up for 24 months. The time points of follow-up were: January, March, June, December, August, and 24 months after discharge. The follow-up method was ward follow-up combined with telephone follow-up. The follow-up included but not limited to the condition/treatment/combination medication and all adverse events.
V. Possible benefits of participating in the study
Although there is already evidence that pancreaticoduodenectomy is satisfactory for treatment, this does not guarantee that it will work for you. The open and laparoscopic methods used in this study are not the only treatments. If your condition is not working, you can ask your doctor about alternative treatments that are possible. 
VI. Adverse reactions, risks and protective measures for participating in the study
During the trial, if there is any discomfort in the study, or the condition changes, or any unexpected situation, regardless of whether it is related to treatment, you should promptly notify your doctor, he/she will make an accurate judgment and medical treatment. deal with. The main adverse reactions and risks are as follows: 1. In the operation, the surgical method is determined according to medical conditions according to the condition;
2. Due to the patient's condition (critical, complicated, poor systemic conditions), individual differences, sudden and sudden recession may occur during and after surgery, multiple organ failure (such as heart failure, respiratory failure, liver failure, renal function) Failure, DIC, etc.) or unpredictable changes in the condition can be life-threatening;
3. Major bleeding, hemorrhagic shock may occur during surgery, and life-threatening; 4. The operation is due to anatomical variation and severe adhesion for therapeutic purposes. It may be inevitable to damage surrounding and nearby tissues and organs, and the corresponding organs need to be repaired or reconstructed; 5. Special medical supplies such as chemotherapy pumps, anastomotic devices, etc. may be used during surgery, and special treatments such as radiofrequency therapy and cryotherapy may be used during surgery;
6. Tumor patients may not be able to undergo surgical resection due to the condition, or recurrence and metastasis after resection, requiring further treatment; Protection measures, if the patients participating in the trial have the above complications, they will form a professional medical team to deal with and treat them for the first time.
VII. The relevant costs
The patient's follow-up examination, such as abdominal color Doppler ultrasound, abdominal CT cost and adjuvant therapy, chemotherapy and other costs will be reduced or even exempted according to different conditions. If an adverse event occurs in a clinical trial, the Medical Expert Committee will determine if it is related to surgery or trial. The treatment and examinations required for other diseases that you have combined at the same time will not be included in the free range.
VIII. The confidentiality of clinical data
Your medical records (research medical records, CRF, test results, etc.) will be kept completely at the hospital where you are attending. The doctor will record the results of the tests and other tests on your medical record. Researchers, ethics committees, and higher-level medical administrations will be allowed to access your medical records. Any public report about the results of this study will not disclose your personal identity. We will make every effort to protect the privacy of your personal medical information to the extent permitted by law.
According to medical research ethics, in addition to personal privacy information, experimental data will be available for public inquiry and sharing. Query and sharing will be limited to web-based electronic databases, ensuring that no personal privacy information will be disclosed.
IX. How can I get more information?
You can ask any questions about this research at any time and get answers.
If there is any important new information during the study that may affect your willingness to continue your research, your doctor will notify you in a timely manner.
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X. You can voluntarily choose to participate in research and withdraw from the study
Whether or not to participate in the research is entirely up to you. You may decline to participate in the study or withdraw from the study at any time during the study, which will not affect your relationship with the doctor and will not affect your medical or other benefits.
For your best interest, your doctor or researcher may discontinue your participation in this study at any time during the course of your research.
XI. What should I do now?
Participation in this clinical study is based on a completely voluntary principle and needs to be carried out with your consent and signed informed consent. Whether or not you participate in this clinical study depends entirely on your own wishes. You have the right to suspend and withdraw from this research treatment at any time. Exiting this study will not affect your medical treatment.
Your physician may suspend your participation in this study in advance if: Your health condition is not suitable for continued participation, or you may not comply with the research program requirements.
The doctor will promptly notify you or your legal representative if there is medical information that may affect your willingness to continue your research during the course of the study. Before you make a decision to participate in this study, please ask your life as much as possible until you fully understand this test study. I fully participated in the study and fully cooperated with the researcher after fully understanding the purpose, method, possible therapeutic benefits and possible risks and other provisions mentioned in the informed consent form.
I understand that I can withdraw from the study at any time and I do not need any reason. The medical services I receive and the legal rights I enjoy are not affected at all.
Finally, I decided to agree to participate in this study and to ensure compliance with my doctor's advice. 
